| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
-Difluoromethylornithine1Brain Tumor Research Center, Department of Neurological Surgery [R. B., S. M. O., L. J. M., M. L., D. F. D.], Department of Laboratory Medicine [L. J. M.], and the Department of Radiation Oncology [D. F. D.], School of Medicine, University of California, San Francisco, California 94143
We have determined the cell cycle age response of 9L rat brain tumor cells to 1,3-bis(2-chloroethyl)-1-nitrosourea using centrifugal elutriation to obtain populations of cells enriched in G1, S, and G2-M phases. While cells in all phases of the cell cycle were killed by 20 or 40 µM 1,3-bis(2-chloroethyl)-1-nitrosourea, cells in G1 and G2-M phases were more sensitive than cells in S phase. The differential sensitivity was more pronounced at the higher dose, which will markedly alter the distribution of cells through the cell cycle. In a clinical setting, this factor could affect the efficacy of either fractionated or multimodality protocols. Treatment with
-difluoromethylornithine, a polyamine biosynthesis inhibitor, potentiated the cytotoxic effects of 20 µM 1,3-bis(2-chloroethyl)-1-nitrosourea against G1- and G2-M- but not against S-phase cells; however, at a higher dose of 1,3-bis(2-chloroethyl)-1-nitrosourea (40 µM), the cytotoxicity was potentiated for cells in all phases of the cell cycle. In
-difluoromethylornithine-treated cells, the phenomenon could be reversed by adding 1 mM putrescine 24 hr before treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea. Therefore, the potentiation of 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity appears to be related to polyamine depletion.
1 Supported by ACS Grant RD-137, NIH Grants CA-13525 and CA-31867, and the Morris Stulsaft Foundation.
2 Recipient of travel grants from the Swedish Natural Science Research Council (R-RA 4685-100) and the Swedish Medical Research Council (B81-04R-6065-504106065).
3 Recipient of a travel grant from the Swedish Natural Science Research Council (R-RA 4818-100).
4 To whom requests for reprints should be addressed at the Brain Tumor Research Center, University of California, San Francisco, Calif. 94143.
Received 5/ 3/82. Accepted 12/16/82.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |